238,822 Shares in Bicara Therapeutics Inc. $BCAX Purchased by Candriam S.C.A.

Candriam S.C.A. acquired a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 238,822 shares of the company’s stock, valued at approximately $4,750,000.

Several other large investors have also modified their holdings of BCAX. UBS Group AG lifted its stake in shares of Bicara Therapeutics by 97.4% during the 4th quarter. UBS Group AG now owns 192,191 shares of the company’s stock worth $3,235,000 after acquiring an additional 94,829 shares during the last quarter. Cantor Fitzgerald L. P. bought a new position in Bicara Therapeutics in the 3rd quarter valued at $1,579,000. Cinctive Capital Management LP bought a new position in Bicara Therapeutics in the 3rd quarter valued at $661,000. Larson Financial Group LLC increased its stake in Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares during the period.

Bicara Therapeutics Stock Down 2.6%

Shares of NASDAQ:BCAX opened at $28.15 on Tuesday. Bicara Therapeutics Inc. has a 52-week low of $9.57 and a 52-week high of $30.99. The stock has a market cap of $1.85 billion, a P/E ratio of -10.13 and a beta of -0.81. The business’s 50 day moving average is $23.56 and its 200 day moving average is $20.19.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). On average, sell-side analysts anticipate that Bicara Therapeutics Inc. will post -3.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Wedbush reiterated an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Citizens Jmp restated a “market outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a report on Tuesday, March 31st. HC Wainwright raised their price target on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Morgan Stanley lifted their price objective on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Finally, Bank of America initiated coverage on shares of Bicara Therapeutics in a research report on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $30.27.

Insider Transactions at Bicara Therapeutics

In other news, COO Ryan Cohlhepp sold 28,214 shares of the firm’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $28.98, for a total transaction of $817,641.72. Following the transaction, the chief operating officer owned 182,177 shares in the company, valued at approximately $5,279,489.46. This trade represents a 13.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Raben sold 5,500 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $22.88, for a total value of $125,840.00. Following the transaction, the insider owned 55,286 shares in the company, valued at approximately $1,264,943.68. This represents a 9.05% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 120,650 shares of company stock worth $3,061,690 over the last quarter. 13.80% of the stock is owned by corporate insiders.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.